Latest Lead News

Atomo Diagnostics reported strong commercial momentum in Q1 FY26, highlighted by a key FDA submission for its FebriDx test and a successful capital raise of $1.3 million. The company also showcased promising clinical data for its Active Syphilis test and expanded its HIV Self-Test distribution channels.

Nick Scali Limited reported a robust $62 million underlying profit for FY25, completed its UK acquisition equity raise, and announced key leadership changes as it eyes accelerated growth in FY26.

CVC Limited is contemplating a fresh offer of Capital Notes, potentially including a reinvestment option for existing holders, contingent on market and regulatory conditions.

Neurizon Therapeutics has secured FDA clearance to resume clinical trials for its lead ALS drug NUZ-001, alongside a $5.2 million capital raise and a key licensing deal with Elanco Animal Health. These developments position the company for a critical growth phase in neurodegenerative disease therapeutics.

Challenger Limited has welcomed APRA’s proposed capital standards for longevity products, highlighting their potential to reduce capital requirements and stimulate growth in Australia’s retirement income sector.

BlinkLab has completed its U.S. autism pilot study with strong diagnostic accuracy and expanded its pivotal FDA trial to seven leading research centers, positioning itself for regulatory submission in late 2026.

Stakk Limited has landed a significant contract with leading U.S. neobank Chime, integrating its embedded finance technology to support millions of users and targeting $8 million in annual recurring revenue by year-end.

Arika Resources has reported exceptional high-grade gold intercepts at its Yundamindra project and expanded its exploration tenure near Kookynie, signalling significant growth potential in Western Australia’s goldfields.

Star Minerals has raised $1.5 million through a share placement to fund critical drilling and mining approvals at its Tumblegum South Gold Project, aiming for production start in early 2026.

Ionic Rare Earths advances its global rare earths strategy with significant UK government funding, increased heavy rare earth oxide production, and a $15.6 million capital raise backed by a strategic US investor.

L1 Group has appointed Julian Russell as its new CEO and Managing Director, marking a strategic leadership transition aimed at capitalising on growth opportunities. Russell’s proven track record in financial services turnaround sets the stage for renewed momentum.

L1 Group Limited has completed the audit of First Maven Pty Ltd’s FY25 financials and released the merged pro forma results combining Platinum Asset Management and L1 Capital. The merged entity reports $305 million in revenue and $177 million in adjusted EBIT, reflecting key merger adjustments and a complex reverse acquisition structure.